Navigation Links
Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
Date:8/19/2007

Combination of Intracranial and Extracranial Resources Benefits Baltimore

Area and Beyond

ATLANTA and BALTIMORE, Aug. 17 /PRNewswire/ -- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine is adding an Elekta Synergy(R) S system to its Leksell Gamma Knife(R) capability. A Stereotactic Center of Excellence, Johns Hopkins aims to fight cancer with both intracranial and extracranial resources for whole-body cancer treatment with the addition of Elekta Synergy S this fall. Elekta Synergy S integrates high- resolution beam shaping, precise target localization, organ motion control and 3D imaging into one package, taking stereotactic radiosurgery and radiotherapy to a new level.

Theodore L. DeWeese, M.D., is Johns Hopkins professor of Radiation Oncology, Oncology and Urology and chair of the Department of Radiation Oncology and Molecular Radiation Sciences. "Elekta Synergy S is an ideal complement to Leksell Gamma Knife radiosurgery," says Dr. DeWeese. "With it, we are expanding stereotactic radiosurgery to other parts of the anatomy besides the brain."

Elekta Synergy S: advanced stereotactic radiation

Elekta Synergy S is an image-guided robotic linear accelerator that combines integrated software-driven imaging abilities with powerful high- resolution radiation delivery. At Johns Hopkins' Kimmel Center, Elekta Synergy S will enable specialists to perform both stereotactic radiosurgery and stereotactic radiotherapy throughout the body, as well as, stereotactic radiosurgery on cranial tumors unsuitable for Gamma Knife surgery.

Essentially, Elekta Synergy S provides Johns Hopkins with the two most important ingredients for improved patient outcomes: 2D and ultra low dose 3D image-guided accuracy and highly conformal beam shaping. This enables neurosurgeons at the Kimmel Center to use extremely precise stereotactic radiosurgery and stereotactic radiotherapy on small-field spinal tumors as well as paraspinal indications with larger field-size requirements.

Johns Hopkins' award-winning legacy

U.S. News & World Report recently named the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center third best in the nation and the top cancer hospital in the Mid-Atlantic Region. The Johns Hopkins Hospital also ranked at the top of its "America's Best Hospitals" Honor roll for the 17th consecutive year.

Elekta Synergy S will be utilized for extracranial radiosurgery, particularly spine and liver applications, says Dr. DeWeese. "The center expects to treat approximately 20 patients per day with Elekta Synergy in the first year," he says, "and about half of those will be stereotactic treatments. Hypofractionated image-guided radiotherapy (IGRT) for prostate applications will follow at a later date as well."

Johns Hopkins also will be using IMPAC for oncology-specific electronic medical records (EMR). IMPAC, an Elekta company, takes oncology management to new levels of efficiency with MOSAIQ(TM), an image-enabled oncology EMR. MOSAIQ supports all aspects of treatment, from patient charting to billing to data and image storage, as well as, patient assessments and access to online clinical images.

Elekta a pioneer in stereotactic radiotherapy and radiosurgery

Elekta Stereotactic Centers of Excellence offer intracranial stereotactic radiosurgery and hypofractionated stereotactic radiosurgery and radiotherapy for applications on all parts of the anatomy. Stereotactic Centers of Excellence are also fully capable of standard radiotherapy treatment, including intensity modulated radiation therapy (IMRT).

Elekta's history of innovation and its advancement of radiotherapy and radiosurgery have made Elekta an industry leader. With the development of Leksell Gamma Knife and the addition of Elekta Synergy S, Elekta provides unprecedented precision and accuracy in stereotactic radiosurgery and stereotactic radiotherapy.

About Elekta

Elekta is an international medical technology group, providing more than 4,000 hospitals worldwide with clinical solutions and comprehensive information systems for improved cancer care and management of brain disorders.

All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective. Elekta is listed on the Nordic Exchange under the ticker EKTAb and the company head office is located in Stockholm, Sweden. For additional information, please visit http://www.elekta.com/proof.


'/>"/>
SOURCE Elekta

Copyright©2007 PR Newswire.

Related biology technology :

1. Johnson Controls deals for asset-tracking software
2. Johnson Controls adds renewable energy unit
3. Johnson Controls unit lands contract for plug-in hybrid battery
4. Johnson Controls to expand in Europe
5. Johnson Controls partners on car satellite linkup
6. Florida schools employ Johnson Controls technology to stop sex predators
7. Johnson Controls partnership wins new contract
8. Johnson Controls appoints Roell to head EOC
9. Johnson Controls reports record quarterly sales
10. SC Johnson issues trademark warning over web offer
11. Research park adds Johnson Controls, Eaton
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
Breaking Biology News(10 mins):